Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Operations: 2015-2025

Historic Cash from Operations for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $2.2 million.

  • Seres Therapeutics' Cash from Operations rose 106.36% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.1 million, marking a year-over-year increase of 85.34%. This contributed to the annual value of -$148.6 million for FY2024, which is 26.63% down from last year.
  • Seres Therapeutics' Cash from Operations amounted to $2.2 million in Q3 2025, which was up 116.60% from -$13.3 million recorded in Q2 2025.
  • Seres Therapeutics' Cash from Operations' 5-year high stood at $127.7 million during Q3 2021, with a 5-year trough of -$76.6 million in Q1 2023.
  • For the 3-year period, Seres Therapeutics' Cash from Operations averaged around -$22.7 million, with its median value being -$35.2 million (2024).
  • Within the past 5 years, the most significant YoY rise in Seres Therapeutics' Cash from Operations was 593.86% (2021), while the steepest drop was 189.30% (2021).
  • Seres Therapeutics' Cash from Operations (Quarterly) stood at -$51.9 million in 2021, then fell by 1.98% to -$52.9 million in 2022, then increased by 10.20% to -$47.5 million in 2023, then climbed by 18.14% to -$38.9 million in 2024, then soared by 106.36% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, -$13.3 million for Q2 2025, and $26.9 million during Q1 2025.